Evidence map›Paper›PMID 30177712›Full record

ArticleScientific reports2018

Promoter Usage and Dynamics in Vascular Smooth Muscle Cells Exposed to Fibroblast Growth Factor-2 or Interleukin-1β.

Ahmad M N Alhendi, Margaret Patrikakis, Carsten O Daub, Hideya Kawaji, Masayoshi Itoh, Michiel de Hoon, Piero Carninci, Yoshihide Hayashizaki, Erik Arner, Levon M Khachigian

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Ahmad M N AlhendiVascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney, 2052, Australia.
Margaret PatrikakisVascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney, 2052, Australia.
Carsten O DaubRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.ORCID 0000-0002-3295-8729
Hideya KawajiRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.ORCID 0000-0002-0575-0308
Masayoshi ItohRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Michiel de HoonRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Piero CarninciRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Yoshihide HayashizakiRIKEN Omics Science Center (OSC), 1-7-22 Suehiro-cho, Tsurumi-ku Yokohama, 230-0045, Japan.
Erik ArnerRIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Levon M KhachigianVascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney, 2052, Australia. L.Khachigian@unsw.edu.au.ORCID 0000-0003-3446-0323
RIKEN Advanced Science Institute · JPRIKEN Center for Integrative Medical Sciences · JPUNSW Sydney · AUScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smooth muscle cells (SMC) in blood vessels are normally growth quiescent and transcriptionally inactive. Our objective was to understand promoter usage and dynamics in SMC acutely exposed to a prototypic growth factor or pro-inflammatory cytokine. Using cap analysis gene expression (FANTOM5 project) we report differences in promoter dynamics for immediate-early genes (IEG) and other genes when SMC are exposed to fibroblast growth factor-2 or interleukin-1β. Of the 1871 promoters responding to FGF2 or IL-1β considerably more responded to FGF2 (68.4%) than IL-1β (18.5%) and 13.2% responded to both. Expression clustering reveals sets of genes induced, repressed or unchanged. Among IEG responding rapidly to FGF2 or IL-1β were FOS, FOSB and EGR-1, which mediates human SMC migration. Motif activity response analysis (MARA) indicates most transcription factor binding motifs in response to FGF2 were associated with a sharp induction at 1 h, whereas in response to IL-1β, most motifs were associated with a biphasic change peaking generally later. MARA revealed motifs for FOS_FOS{B,L1}_JUN{B,D} and EGR-1..3 in the cluster peaking 1 h after FGF2 exposure whereas these motifs were in clusters peaking 1 h or later in response to IL-1β. Our findings interrogating CAGE data demonstrate important differences in promoter usage and dynamics in SMC exposed to FGF2 or IL-1β.

Indexed as

Genes, Immediate-EarlyPromoter Regions, GeneticCell MovementCell ProliferationCulture Media, Serum-FreeEarly Growth Response Protein 1Fibroblast Growth Factor 2Gene Expression ProfilingGene Expression RegulationHumansInterleukin-1betaMyocytes, Smooth MuscleNucleotide MotifsPrimary Cell CultureProtein BindingProto-Oncogene Proteins c-fosCulture Media, Serum-FreeEarly Growth Response Protein 1EGR1 protein, humanFibroblast Growth Factor 2FOSB protein, humanFOS protein, humanIL1B protein, humanInterleukin-1betaProto-Oncogene Proteins c-fos

Identifiers

PMID30177712
PMCPMC6120868
OpenAlexW2889452223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.